Small profit and cash dividend at Pharma-Bio Serv (NASDAQ: PBSV) Q1 2026

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. reported nearly flat operations but remained profitable for the quarter ended January 31, 2026. Revenue was about $2.3 million, down from $2.5 million a year earlier, as U.S. and Europe consulting projects declined while Puerto Rico inched up.

Gross margin was stable at 31.5%, with a small operating loss of $94,535 offset by $131,025 of other income, mainly interest and foreign exchange gains, yielding net income of $32,860. Earnings per share were effectively breakeven at $0.001.

The company ended the quarter with $5.8 million in cash and $4.8 million in marketable U.S. Treasury securities, and working capital of about $10 million. It declared a $0.075 per-share cash dividend (about $1.72 million) and repurchased 3,100 shares at $0.54. Headquarters moved to a virtual model after its only long-term lease expired, and management believes existing resources are sufficient to fund operations beyond the next twelve months.

0001304161false--10-31Q120260.00011000000000000.000150000000falsefalsefalsefalse530000037335000013041612025-11-012026-01-310001304161pbsv:OtherSegmentMember2025-11-012026-01-310001304161pbsv:OtherSegmentMember2024-11-012025-01-310001304161pbsv:EuropeConsultingMember2025-11-012026-01-310001304161pbsv:EuropeConsultingMember2024-11-012025-01-310001304161pbsv:UnitedStatesConsultingMember2025-11-012026-01-310001304161pbsv:UnitedStatesConsultingMember2024-11-012025-01-310001304161pbsv:PuertoRicoConsultingMember2025-11-012026-01-310001304161pbsv:PuertoRicoConsultingMember2024-11-012025-01-310001304161us-gaap:AccountsReceivableMemberpbsv:GlobalLevelCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMemberpbsv:GlobalLevelCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMemberpbsv:GlobalLevelCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMemberpbsv:GlobalLevelCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMemberpbsv:GlobalLevelCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMemberpbsv:GlobalLevelCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMemberpbsv:GlobalLevelCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelFourCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelThreeCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelTwoCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelOneCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelFourCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelThreeCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelTwoCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelOneCustomerMember2024-11-012025-01-310001304161us-gaap:AccountsReceivableMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:FourCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:FourCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:ThreeCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:ThreeCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:TwoCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:TwoCustomerMember2025-11-012026-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:OneCustomerMember2024-11-012025-01-310001304161us-gaap:SalesRevenueNetMemberpbsv:OneCustomerMember2025-11-012026-01-3100013041612025-01-2800013041612025-01-012025-01-280001304161us-gaap:EmployeeStockOptionMember2025-11-012026-01-310001304161us-gaap:EmployeeStockOptionMember2024-11-012025-01-310001304161pbsv:PRIDCOMember2025-11-012026-01-310001304161pbsv:TaxReformMember2017-12-220001304161pbsv:TaxReformMember2025-11-012026-01-310001304161us-gaap:TreasuryStockCommonMember2026-01-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-310001304161us-gaap:RetainedEarningsMember2026-01-310001304161us-gaap:AdditionalPaidInCapitalMember2026-01-310001304161us-gaap:PreferredStockMember2026-01-310001304161us-gaap:CommonStockMember2026-01-310001304161us-gaap:TreasuryStockCommonMember2025-11-012026-01-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-11-012026-01-310001304161us-gaap:RetainedEarningsMember2025-11-012026-01-310001304161us-gaap:AdditionalPaidInCapitalMember2025-11-012026-01-310001304161us-gaap:PreferredStockMember2025-11-012026-01-310001304161us-gaap:CommonStockMember2025-11-012026-01-310001304161us-gaap:TreasuryStockCommonMember2025-10-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-10-310001304161us-gaap:RetainedEarningsMember2025-10-310001304161us-gaap:AdditionalPaidInCapitalMember2025-10-310001304161us-gaap:PreferredStockMember2025-10-310001304161us-gaap:CommonStockMember2025-10-3100013041612025-01-310001304161us-gaap:TreasuryStockCommonMember2025-01-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-310001304161us-gaap:RetainedEarningsMember2025-01-310001304161us-gaap:AdditionalPaidInCapitalMember2025-01-310001304161us-gaap:PreferredStockMember2025-01-310001304161us-gaap:CommonStockMember2025-01-310001304161us-gaap:TreasuryStockCommonMember2024-11-012025-01-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-11-012025-01-310001304161us-gaap:RetainedEarningsMember2024-11-012025-01-310001304161us-gaap:AdditionalPaidInCapitalMember2024-11-012025-01-310001304161us-gaap:PreferredStockMember2024-11-012025-01-310001304161us-gaap:CommonStockMember2024-11-012025-01-3100013041612024-10-310001304161us-gaap:TreasuryStockCommonMember2024-10-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-310001304161us-gaap:RetainedEarningsMember2024-10-310001304161us-gaap:AdditionalPaidInCapitalMember2024-10-310001304161us-gaap:PreferredStockMember2024-10-310001304161us-gaap:CommonStockMember2024-10-3100013041612024-11-012025-01-3100013041612025-10-3100013041612026-01-3100013041612026-03-13iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ______________

Commission File No. 000-50956

Pharma-Bio Serv, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		20-0653570
(State or Other Jurisdiction of Incorporation or Organization)		(IRS  Employer  Identification No.)

Pharma-Bio Serv Building, PO Box 1049 Dorado, Puerto Rico		00646
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code 787-278-2709

N/A

  (Former name, former address and former fiscal year, if changed since last report)  

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class Trading Symbol(s) Name of each exchange on which registered

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock outstanding as of March 13, 2026 was 22,901,692.

PHARMA-BIO SERV, INC.

FORM 10-Q

FOR THE QUARTER ENDED JANUARY 31, 2026

TABLE OF CONTENTS

		Page
PART I FINANCIAL INFORMATION
Item 1 – Financial Statements			3
Condensed Consolidated Balance Sheets as of January 31, 2026 and October 31, 2025 (unaudited)			3
Condensed Consolidated Statements of Operations for the three-month periods ended January 31, 2026 and 2025 (unaudited)			4
Condensed Consolidated Statements of Comprehensive Income (Loss) for the three-month periods ended January 31, 2026 and 2025 (unaudited)			5
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three-month periods ended January 31, 2026 and 2025 (unaudited)			6
Condensed Consolidated Statements of Cash Flows for the three-month periods ended January 31, 2026 and 2025 (unaudited)			7
Notes to Condensed Consolidated Financial Statements (unaudited)			8
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations			14
Item 4 – Controls and Procedures			17
PART II OTHER INFORMATION
Item 1 – Legal Proceedings			18
Item 1A – Risk Factors			18
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds			18
Item 6 – Exhibits			19
SIGNATURES			20

2

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

PHARMA-BIO SERV, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

ASSETS		January 31, 2026*				October 31, 2025**
Current assets
Cash and cash equivalents		$	5,763,618			$	3,379,212
Marketable securities			4,796,568				7,475,377
Accounts receivable			2,654,675				2,360,682
Prepaids and other assets			109,108				171,574
Total current assets			13,323,969				13,386,845
Property and equipment			103,674				116,059
Operating lease right-of-use			-				29,388
Other assets			120,783				120,754
Total assets		$	13,548,426			$	13,653,046
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Current operating lease liabilities		$	-			$	28,834
Accounts payable and accrued expenses			869,964				991,169
Dividend payable to shareholders			1,717,627				-
Current portion of US Tax Reform Transition Tax and income taxes payable			722,104				718,796
Total current liabilities			3,309,695				1,738,799
Total liabilities			3,309,695				1,738,799
Stockholders' equity
Preferred Stock, $0.0001 par value; authorized 10,000,000 shares; none outstanding			-				-
Common Stock, $0.0001 par value; authorized 50,000,000 shares; 23,519,672 and 23,519,672 shares issued, and 22,902,892 and 22,905,992 shares outstanding on January 31, 2026 and October 31, 2025, respectively			2,352				2,352
Additional paid-in capital			1,688,166				1,679,547
Retained earnings			8,848,822				10,533,589
Accumulated other comprehensive income			280,358				278,045
			10,819,698				12,493,533
Treasury stock, at cost; 616,780 and 613,680 common shares held on January 31, 2026 and October 31, 2025, respectively			(580,967	)			(579,286	)
Total stockholders' equity			10,238,731				11,914,247
Total liabilities and stockholders' equity		$	13,548,426			$	13,653,046

*	Unaudited.
**	Condensed from audited financial statements.

See notes to the condensed consolidated financial statements.

3

Table of Contents

PHARMA-BIO SERV, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

		Three months ended January 31,
		2026				2025
REVENUES		$	2,294,966			$	2,471,333
COST OF SERVICES			1,572,592				1,703,224
GROSS PROFIT			722,374				768,109
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES			816,909				860,300
LOSS FROM OPERATIONS			(94,535	)			(92,191	)
OTHER INCOME, NET			131,025				101,842
INCOME BEFORE INCOME TAX			36,490				9,651
INCOME TAX EXPENSE			3,630				1,115
NET INCOME		$	32,860			$	8,536
BASIC AND DILUTED EARNINGS  PER COMMON SHARE		$	0.001			$	0.000
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC			22,905,743				22,958,143
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED			22,912,954				22,960,752

See notes to the condensed consolidated financial statements.

4

Table of Contents

PHARMA-BIO SERV, INC.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

		Three months ended January 31,
		2026				2025
NET INCOME		$	32,860			$	8,536
OTHER COMPREHENSIVE INCOME (LOSS):
Foreign currency translation:
Net unrealized gain (loss)			36,241				(47,363	)
Intercompany balances foreign exchange settlement, included in net income			(33,928	)			28,866
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)			2,313				(18,497	)
COMPREHENSIVE INCOME (LOSS)		$	35,173			$	(9,961	)

See notes to the condensed consolidated financial statements.

5

Table of Contents

PHARMA-BIO SERV, INC.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(Unaudited)

																										Accumulated Other
																		Additional								Comprehensive
FISCAL YEAR 2026		Common Stock								Preferred Stock								Paid-in				Retained				Income				Treasury
(THREE MONTHS ENDED JANUARY 31, 2026)		Shares				Amount				Shares				Amount				Capital				Earnings				(Loss)				Stock				Total
BALANCE AT NOVEMBER 1, 2025			23,519,672			$	2,352				-			$	-			$	1,679,547			$	10,533,589			$	278,045			$	(579,286	)		$	11,914,247
STOCK-BASED COMPENSATION			-				-				-				-				8,619				-				-				-				8,619
PURCHASE OF TREASURY STOCK (3,100 SHARES)			-				-				-				-				-				-				-				(1,681	)			(1,681	)
NET INCOME			-				-				-				-				-				32,860				-				-				32,860
OTHER COMPREHENSIVE INCOME, NET OF TAX			-				-				-				-				-				-				2,313				-				2,313
CASH DIVIDEND ($0.075 PER COMMON SHARE AT RECORD DATE)			-				-				-				-				-				(1,717,627	)			-				-				(1,717,627	)
BALANCE AT JANUARY 31, 2026			23,519,672			$	2,352				-			$	-			$	1,688,166			$	8,848,822			$	280,358			$	(580,967	)		$	10,238,731

																										Accumulated Other
																		Additional								Comprehensive
FISCAL YEAR 2025		Common Stock								Preferred Stock								Paid-in				Retained				Income				Treasury
(THREE MONTHS ENDED JANUARY 31, 2025)		Shares				Amount				Shares				Amount				Capital				Earnings				(Loss)				Stock				Total
BALANCE AT NOVEMBER 1, 2024			23,519,672			$	2,352				-			$	-			$	1,644,468			$	12,353,970			$	262,380			$	(547,843	)		$	13,715,327
STOCK-BASED COMPENSATION			-				-				-				-				10,681				-				-				-				10,681
NET INCOME			-				-				-				-				-				8,536				-				-				8,536
OTHER COMPREHENSIVE LOSS, NET OF TAX			-				-				-				-				-				-				(18,497	)			-				(18,497	)
CASH DIVIDEND ($0.075 PER COMMON SHARE AT RECORD DATE)			-				-				-				-				-				(1,719,918	)			-				-				(1,719,918	)
BALANCE AT JANUARY 31, 2025			23,519,672			$	2,352				-			$	-			$	1,655,149			$	10,642,588			$	243,883			$	(547,843	)		$	11,996,129

See notes to condensed consolidated financial statements.

6

Table of Contents

PHARMA-BIO SERV, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

		Three months ended January 31,
		2026				2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	32,860			$	8,536
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Gain on disposition of vehicle			(7,000	)			-
Stock-based compensation			8,619				10,681
Depreciation and amortization			14,796				9,439
Amortization of operating lease right-of-use			29,388				41,386
Reinvested interests			(83,346	)			(137,759	)
Increase in accounts receivable			(277,116	)			(186,365	)
Decrease in other assets			39,716				37,737
Decrease in liabilities			(148,056	)			(213,141	)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES			(390,139	)			(429,486	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment			(2,411	)			-
Proceeds from sale of vehicle			7,000				-
Marketable securities investments, net			2,762,155				988,338
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES			2,766,744				988,338
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase of common stock			(1,681	)			-
CASH USED IN FINANCING ACTIVITIES			(1,681	)			-
EFFECT OF EXCHANGE RATE CHANGES ON CASH			9,482				(19,085	)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			2,384,406				539,767
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD			3,379,212				6,767,356
CASH AND CASH EQUIVALENTS - END OF PERIOD		$	5,763,618			$	7,307,123
SUPPLEMENTARY SCHEDULES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Income tax withheld by clients to be used as a credit in the Company’s income tax return		$	14,538			$	-
Cash dividend declared but not paid		$	1,717,627			$	1,719,918
Decommissioned fully depreciated and/or amortized old property and equipment written off during the three months ended January 31, 2026		$	69,043			$	-

See notes to the condensed consolidated financial statements.

7

Table of Contents

PHARMA-BIO SERV, INC.

Notes To Condensed Consolidated Financial Statements

January 31, 2026

(Unaudited)

NOTE A - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION

Pharma-Bio Serv, Inc. (“Pharma-Bio”) is a Delaware corporation organized on January 14, 2004. Pharma-Bio is the parent company of Pharma-Bio Serv PR, Inc. (“Pharma-PR”), Pharma Serv, Inc. (“Pharma-Serv”), and Scienza Labs, Inc. (currently inactive) (“Scienza Labs”), each a Puerto Rico corporation, Pharma-Bio Serv US, Inc. (“Pharma-US”), a Delaware corporation, Pharma-Bio Serv SL (“Pharma-Spain”), a Spanish limited liability company, and Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. (currently insignificant) (“Pharma-Brazil”), a Brazilian limited liability company. Pharma-Bio, Pharma-PR, Pharma-Serv, Scienza Labs, Pharma-US, Pharma-Spain and Pharma-Brazil are collectively referred to as the “Company.” The Company operates in Puerto Rico, the United States, Spain and Brazil under the name of Pharma-Bio Serv and is engaged in providing technical compliance consulting service.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The condensed consolidated balance sheet of the Company as of October 31, 2025 is derived from audited consolidated financial statements but does not include all disclosures required by generally accepted accounting principles. The unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position and results of operations and cash flows for the interim periods. The results of operations for the three months ended January 31, 2026 are not necessarily indicative of expected results for the full 2026 fiscal year.

The accompanying financial data as of January 31, 2026, and for the three-month period ended January 31, 2026 and 2025 has been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally contained in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes contained in our audited Consolidated Financial Statements and the notes thereto for the fiscal year ended October 31, 2025.

Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Segments

The Company operates in three reportable business segments: (i) Puerto Rico technical compliance consulting, (ii) United States technical compliance consulting, and (iii) Europe technical compliance consulting. Accordingly, the accompanying condensed consolidated financial statements are presented to show these three reportable segments.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from these estimates.

8

Table of Contents

Fair Value of Financial Instruments

Accounting standards have established a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Accounting standards have established three levels of inputs that may be used to measure fair value:

	Level 1:	Quoted prices in active markets for identical assets and liabilities.
	Level 2:	Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3:	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Marketable securities consist of U.S. Treasury securities, which are categorized in Level 1 and have a short-term maturity.

The carrying value of the Company's financial instruments, cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature.

Revenue Recognition

The Company records revenue under Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers. We evaluate our revenue contracts with customers based on the five-step model under ASC 606: (i) Identify the contract with the customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to separate performance obligations; and (v) Recognize revenue when (or as) each performance obligation is satisfied.

Revenue is primarily derived from: (1) time and material contracts (representing approximately 99% of total revenues), and (2) short-term fixed-fee contracts or "not to exceed" contracts (representing approximately 1% of total revenues).  Time and material contracts are typically based on the number of hours worked at contractually agreed upon rates. These service contracts relate to work which has no alternative use and for which the Company has an enforceable right to payment for the work completed to date. As a result, revenue is recognized over time when or as the Company transfers control of the promised products or services (known as performance obligations) to its customers. Revenue for short term fixed fee contracts or “not to exceed” contracts is recognized similarly, except that certain milestones also have to be reached before revenue is recognized. If the Company determines that a contract will result in a loss, the Company recognizes the estimated loss in the period in which such determination is made.

Cash Equivalents

For purposes of the condensed consolidated statements of cash flows, cash equivalents consist of cash and liquid investments, including U.S. Treasury securities, with original maturities of three months or less.

Accounts Receivable

Accounts receivable are reported net of an allowance for credit losses. The Company maintains an allowance for credit losses to provide for estimated amounts of receivables that will not be collected. This estimation is based on historical collection experience, the age of the receivables, an assessment of the creditworthiness of customers, and current economic conditions. The allowance for credit losses is subject to estimation uncertainty. If actual future uncollectible amounts differ from estimates, future provisions for credit losses may be affected. The allowance is increased by provisions charged to credit loss expense and reduced by charge-offs of uncollectible accounts. As of January 31, 2026 and October 31, 2025, the allowance for credit losses was approximately $5.3 million, and there were no charges to expense or charge-offs of uncollectible accounts during the three months ended on January 31, 2026 and 2025. The existing allowance is mostly related to an account that is being litigated, which was fully allowed in 2021.

Income Taxes

The Company follows an asset and liability approach method of accounting for income taxes. This method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

The Company follows guidance from the Financial Accounting Standards Board (“FASB”) related to Accounting for Uncertainty in Income Taxes, which includes a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions. As of January 31, 2026, the Company had no significant uncertain tax positions that would be reduced as a result of a lapse of the applicable statute of limitations.

9

Table of Contents

Leases

The Company follows accounting standards issued by the FASB for the accounting and disclosure of leases. Under those standards, assets and liabilities that arise from leases are recognized on the balance sheet, and the leases are categorized at their inception as either operating or finance leases.

Operating lease right-of-use assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term, based on a discount rate of 8%. On December 31, 2025 the Company terminated the only contractual long-term lease it had.

Property and Equipment

Owned property and equipment are stated at cost. Depreciation and amortization of owned assets is provided for, when placed in service, in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service lives, using straight-line basis. Expenditures for repairs and maintenance are expensed when incurred. As of January 31, 2026 and October 31, 2025, the accumulated depreciation and amortization amounted to $149,088 and $199,929, respectively.

Impairment of Long-Lived Assets

The Company evaluates for impairment its long-lived assets to be held and used, and long-lived assets to be disposed of, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Based on management estimates, no impairment of the long-lived assets was present as of January 31, 2026 and October 31, 2025.

Stock-based Compensation

Stock-based compensation expense is recognized in the condensed consolidated financial statements based on the fair value of the awards granted. Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of awards that will be forfeited. The Company calculates the fair value of stock options using the Black-Scholes option-pricing model at the grant date, while for restricted stock units the fair market value of the units is determined by the Company’s share market value at grant date. Excess tax benefits related to stock-based compensation are reflected as cash flows from financing activities rather than cash flows from operating activities. The Company has not recognized such cash flows from financing activities since there has been no tax benefit related to the stock-based compensation.

Earnings Per Share of Common Stock

Basic earnings per share of common stock is calculated by dividing net earnings by the weighted average number of shares of common stock outstanding. Diluted earnings per share includes the dilution of common stock equivalents, which include principally shares that may be issued upon the exercise of warrants, stock option and restricted stock unit awards.

The diluted weighted average shares of common stock outstanding were calculated using the treasury stock method for the respective periods.

Foreign Operations

The functional currency of the Company’s foreign subsidiaries is its local currency. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for subsidiaries using a functional currency other than the U.S. dollar is included as a cumulative translation adjustment in stockholders’ equity and as a component of comprehensive income (loss).

The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in stockholders’ equity and as a component of comprehensive income (loss), while gains and losses resulting from the remeasurement of intercompany receivables from those international subsidiaries for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations.

Subsequent Events

The Company has evaluated subsequent events through the filing date of this report. The Company has determined that there are no events occurring in this period that require disclosure or adjustment.

10

Table of Contents

Reclassifications

Certain reclassifications have been made to the January 31, 2025 condensed consolidated financial statements to conform them to the January 31, 2026 condensed consolidated financial statements presentation. Such reclassifications do not affect net income as previously reported.

Recent Accounting Pronouncements

The Financial Accounting Standards Board (FASB) establishes the FASB Accounting Standards Codification (ASC) as the single source of authoritative U.S. GAAP. New standards are communicated through an Accounting Standards Update (ASU). The Company considers the applicability and impact of all ASUs. However, the Company has evaluated the possible impact of standards still not implemented and does not foresee that the implementation of those standards in the future may have any significant effect on the condensed consolidated financial statements.

NOTE B – MARKETABLE SECURITIES

Marketable securities consist of U.S. Treasury securities with maturities over three months, which are held until maturity and accordingly, are measured at cost plus accreted interest income.

NOTE C - INCOME TAXES

On December 22, 2017, Public Law 115-97, commonly known as the Tax Cuts and Jobs Act of 2017 (the “TCJA”), was enacted. TCJA imposed a mandatory one-time transition tax (the “Transition Tax”) over foreign subsidiaries undistributed earnings and profits (“E&Ps”) earned prior to a date set by the statute. Based on the Company’s E&Ps, the Transition Tax was determined to be approximately $2.7 million. The Transition Tax liability must be paid over a period of eight years, which started with the Company’s second quarter of fiscal year 2019 and ends in the second quarter of fiscal year 2026. Previously, most of these E&Ps’ were not repatriated since such E&Ps’ were considered to be reinvested indefinitely in the foreign location, therefore no US tax liability was incurred unless the E&Ps were repatriated as a dividend. After December 31, 2017, the TCJA established a 100% tax exemption on the foreign-source portion of dividends received attributable to E&Ps, with certain limitations.

On July 4, 2025, Public Law 119-21, One, Big, Beautiful, Bill Act (“OBBBA”) was enacted and changed the GILTI provisions that were part of the TCJA for taxing foreign subsidiaries earnings. OBBBA renames the GILTI provision to “net CFC tested income” and increases the effective tax rate on net CFC tested income from 10.5% to approximately 12.6%. Also, OBBBA includes some limitations on foreign tax credits, if any, to be used against net CFC tested income. The Company will be subject to the above named OBBBA provisions effective with our fiscal year ended October 31, 2027. We are currently assessing its impact on our consolidated financial statements.

In June 2011, Pharma-Bio, Pharma-PR and Pharma-Serv obtained a Grant of Industrial Tax Exemption pursuant to the terms and conditions set forth in Act No. 73 of May 28, 2008 (“the Grant”) issued by the Puerto Rico Industrial Development Company (“PRIDCO”). The Grant was effective as of November 1, 2009, and covered a fifteen-year period which expired on October 31, 2024. Under the provisions of Puerto Rico Acts 60-2019 and 73-2008, the Company requested that PRIDCO extend the Grant for an additional term of fifteen years. As of the date of this filing, we have not received a status update from PRIDCO for this request. Furthermore, under ACT 20-2012, the Company obtained another tax grant from PRIDCO which, with certain limitations, also covers the services provided by the Company’s Puerto Rico subsidiaries to parties located outside of Puerto Rico. The ACT 20-2012 tax grant is for a twenty-year term which ends on December 30, 2039. The income generated under the provisions of the above-mentioned grants is subject to a fixed income tax rate of 4%, and the related earnings are exempt from Puerto Rico earnings distribution tax.

Puerto Rico operations not covered in the exempt activities of the Grant are subject to Puerto Rico income tax at a maximum tax rate of 37.5% as provided by the 1994 Puerto Rico Internal Revenue Code, as amended. The operations conducted in the United States by the Company’s subsidiaries, is taxed in the United States at a maximum regular federal income tax rate of 21%. The Spanish subsidiary operations in Spain are taxed at a regular income tax rate of 25%.

Deferred income tax assets and liabilities are computed for differences between the condensed consolidated financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Realization of future tax benefits related to a deferred tax asset is dependent on many factors. Accordingly, the income tax benefit will be recognized when realization is determined to be more probable than not.

The Company files income tax returns in the United States (federal and various states jurisdictions), Puerto Rico, Spain and Brazil. The 2021 (2020 for Puerto Rico) through 2025 tax years are open and may be subject to potential examination in one or more jurisdictions. Currently, the Company is not subject to a federal, state, Puerto Rico or foreign income tax examination.

11

Table of Contents

NOTE D – EARNINGS PER SHARE

The following data shows the amounts used in the calculations of basic and diluted earnings per share.

		Three months ended January 31,
		2026				2025
Net income available to common equity holders - used to compute basic and diluted earnings per share		$	32,860			$	8,536
Weighted average number of common shares - used to compute basic earnings per share			22,905,743				22,958,143
Effect of options to purchase common stock			7,211				2,609
Weighted average number of shares - used to compute diluted earnings per share			22,912,954				22,960,752

Options for the purchase of 373,350 shares of common stock for the three-month periods ended on January 31, 2026 and 2025 were not included in computing diluted earnings per share because their effects were antidilutive.

NOTE E – EQUITY TRANSACTIONS

On June 13, 2014, the Board of Directors of the Company authorized the Company to repurchase up to two million shares of its outstanding common stock under the Company Stock Repurchase Program (the “Repurchase Program”). The timing, manner, price and amount of any repurchases under the Repurchase Program will be at the discretion of the Company, subject to the requirements of the Securities Exchange Act of 1934, as amended, and related rules. The Repurchase Program does not oblige the Company to repurchase any shares, and it may be modified, suspended or terminated at any time and for any reason. No shares will be repurchased under the Repurchase Program directly from directors or officers of the Company. As of January 31, 2026 and October 31, 2025, a total of 553,808 and 550,708 shares of the Company’s common stock has been purchased under the Repurchase Program for an aggregate amount of $517,996 and $516,314, respectively.

On January 28, 2026, the Board of Directors of the Company declared a cash dividend of $0.075 per common share for shareholders of record as of the close of business on February 27, 2026. Accordingly, an aggregate estimated dividend payment of $1,717,627 will be paid on or about March 20, 2026.

NOTE F - CONCENTRATIONS OF RISK

Cash, Cash Equivalents and Marketable Securities

The Company’s domestic cash and cash equivalents, and marketable securities consist of cash deposits in FDIC insured banks (substantially covered by FDIC insurance by the spread of deposits in multiple FDIC insured banks), and U.S. Treasury securities with maturities of twelve months or less. The U.S. Treasury securities are held in the custody of major financial institutions and their value is not subject to insurance.  In the foreign markets we serve, we also maintain cash deposits in foreign banks, which have no specific insurance. Normally, these uninsured bank deposits are not significant, and they are in deposit with major multinational banks. No significant losses have been experienced nor are expected on these bank accounts or investments.

Accounts receivable and revenues

The Company's revenues, and the related receivables, are concentrated in the pharmaceutical industry in Puerto Rico, the United States of America and Europe. Although a few customers represent a significant source of revenue, the Company’s functions are not a continuous process, accordingly, the client base for which the services are typically rendered, on a project-by-project basis, changes regularly.

The Company provided a substantial portion of its services to four customers, which accounted for 10% or more of its revenues in either of the three-month periods ended January 31, 2026 and 2025. During the three months ended January 31, 2026, revenues from these customers were 16.1%, 15.5%, 13.5% and 0.0%, or a total of 45.1%, as compared to the percentages for the same period last year of 0.0%, 11.8%, 15.7% and 22.2%, or a total of 49.7%, respectively. For the three months ended January 31, 2026 and 2025, these customers represented for the Puerto Rico, United States and Europe consulting reportable segments 15.5%, 13.5% and 16.1%, as compared to 11.8%, 15.7% and 22.2%, respectively. On January 31, 2026, amounts due from these customers represented 40.7% of the Company’s total accounts receivable balance.

12

Table of Contents

The information related to major customers in the above paragraph is based on revenues earned from said customers at the segment level because in management’s opinion contracts by segments are independent of each other, and therefore such information is more meaningful to the reader. However, at the global level four customers accounted for 10% or more of the Company’s revenues in either of the three-month periods ended January 31, 2026 and 2025. During the three months ended January 31, 2026, aggregate revenues from these global groups of affiliated companies were 16.1%, 15.5%, 15.0% and 0.0%, or a total of 46.6%, as compared to the same period last year for 0.0%, 11.8%, 17.4% and 22.2%, or a total of 51.4%, respectively. For the three months ended January 31, 2026 and 2025, these customers represented for the Puerto Rico, United States and Europe consulting reportable segments 17.0%, 13.5% and 16.1%, as compared to 13.5%, 15.7% and 22.2%, respectively. On January 31, 2026, amounts due from these global groups of affiliated companies represented 43.0% of total accounts receivable balance.

NOTE G - SEGMENT DISCLOSURES

The Company’s segments are based on the organizational structure for which financial results are regularly evaluated by the Company’s Chief Executive Officer, which is our chief operating decision maker (the “CODM”), to determine resource allocation and assess performance. Each reportable segment is managed by its own management team and reports to executive management. The Company has three reportable segments: (i) Puerto Rico consulting, (ii) United States consulting, and (iii) Europe consulting. The reportable segments provide services primarily to the pharmaceutical, chemical, medical device and biotechnology industries in their respective markets. The services vary between customers and projects based on the nature of the project and the technical skills necessary to accomplish the project tasks. Therefore, the allocation of consultancy resources is mostly based on the segment’s ability to provide the best consultant in the most profitable cost-effective manner. Accordingly, the CODM evaluates segment performance based on the segment’s (i) revenue volume, (ii) gross profit ratio to revenue, and (iii) income (loss) from operations.

The following table presents information about the reported revenue from services and income (loss) from operations of the Company for the three-month periods ended January 31, 2026 and 2025. There is no intersegment revenue for the mentioned periods. Corporate expenses that support the operating units have been allocated to the segments. Asset information by reportable segment is not presented, since the Company does not produce such information internally, nor does it use such data to manage its business.

		Three months ended January 31,
		2026								2025
REVENUES:
Puerto Rico consulting		$	1,164,183							$	1,103,269
United States consulting			546,888								646,133
Europe consulting			583,895								721,258
Other			-								673
Total consolidated revenue		$	2,294,966							$	2,471,333
GROSS PROFIT¹:
Puerto Rico consulting		$	250,871				21.5	%		$	197,554				17.9	%
United States consulting			205,663				37.6	%			222,325				34.4	%
Europe consulting			265,840				45.5	%			347,557				48.2	%
Other			-				-	%			673				100.0	%
Total consolidated gross profit		$	722,374				31.5	%		$	768,109				31.1	%
INCOME (LOSS) FROM OPERATIONS2:
Puerto Rico consulting		$	(23,129	)						$	(44,769	)
United States consulting			(59,868	)							(100,062	)
Europe consulting			10,881								66,381
Other			(22,419	)							(13,741	)
Total consolidated loss from operations			(94,535	)							(92,191	)
OTHER INCOME, NET			131,025								101,842
Total consolidated income before income tax		$	36,490							$	9,651
1 Gross profit represents revenues less cost of service, which the latter is mostly composed of personnel cost. Percentages represent the segment(s) gross profit to its related revenue segment(s).
2 Income (loss) from operations represents gross profit reduced by selling, general and administrative expenses.

Long lived assets (property and equipment) as of January 31, 2026 and October 31, 2025, and related depreciation and amortization expense for the three months ended January 31, 2026 and 2025, were concentrated in the corporate offices in Puerto Rico. Accordingly, depreciation expense and acquisition of property and equipment, as presented in the condensed consolidated statements of cash flows, are mainly related to the corporate offices.

13

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion of our results of operations and financial condition should be read in conjunction with the financial statements and the related notes included under Part I, Item 1 of this Quarterly Report on Form 10-Q. In addition, reference should be made to our audited Consolidated Financial Statements and notes thereto, and related Management’s Discussion and Analysis of Financial Condition and Results of Operations appearing in our Annual Report on Form 10-K for the year ended October 31, 2025. The following discussion includes forward-looking statements. For a discussion of important factors that could cause actual results to differ from results discussed in the forward-looking statements, see “Forward Looking Statements” below and the “Risk Factors” section of our Annual Report on Form 10-K for the year ended October 31, 2025 and this Quarterly Report on Form 10-Q.

Overview

We are a compliance and technology transfer services consulting firm with headquarters in Puerto Rico, servicing the Puerto Rico, United States and Europe markets, with limited presence in the Brazil market. The compliance consulting service sector in those markets consists of local compliance and validation consulting firms, United States dedicated validation and compliance consulting firms and large publicly traded and private domestic and foreign engineering and consulting firms. We provide a broad range of compliance-related consulting services. We market our services to pharmaceutical, chemical, biotechnology, medical devices, cosmetics and food industries, and allied products companies. Our consulting team includes experienced engineering and life science professionals, former quality assurance managers and directors, and professionals with bachelors, masters and doctorate degrees in health sciences and engineering.

We actively operate in Puerto Rico, the United States, Europe and, to a lesser extent, Brazil and pursue to further expand these markets by strengthening our business development infrastructure and by constantly realigning our business strategies as new opportunities and challenges arise.

We market our services with an active presence in industry trade shows, professional conventions, industry publications and company-provided seminars to the industry. Our senior management is also actively involved in the marketing process, especially in marketing to major accounts. Our senior management and staff also concentrate on developing new business opportunities and focus on the larger customer accounts (by number of consultants or dollar volume) and responding to prospective customers’ requests for proposals.

We consider our core business to be Food and Drug Administration (“FDA”) and international agencies regulatory compliance consulting related services.

The Company held a tax grant issued by PRIDCO, which provided relief on various Puerto Rico taxes, including income tax, with certain limitations, for most of the activities conducted within Puerto Rico, including those that are for services to parties located outside of Puerto Rico. The grant was effective as of November 1, 2009, and covered a fifteen-year period, which ended on October 31, 2024. Under the provisions of Puerto Rico Acts 60-2019 and 73-2008, we have requested PRIDCO renegotiation of the tax grant for an additional term of fifteen years.  As of the date of this filing, we have not received a status update from PRIDCO for that tax grant request. However, we do not anticipate any significant concerns with the Grant approval. Under ACT 20-2012, the Company obtained another tax grant from PRIDCO which, with certain limitations, also covers the services provided by the Company’s Puerto Rico subsidiaries to parties located outside of Puerto Rico. The ACT 20-2012 tax grant is for a twenty-year term which ends on December 30, 2039. For additional information relating to the tax grant issued by PRIDCO, please see Note C – Income Taxes of the condensed consolidated financial statements.

The Company’s headquarters office facilities lease expired on December 31, 2025. Prior to the lease’s expiration, the Company vetted various technologies which resulted in the Company moving its headquarters administrative operations to a virtual landscape. The move will enable us to maintain the same level of service in a more competitive manner.

Regional or global conflicts, including war and economic sanctions between nations, price inflation, pandemics, OBBBA, possible tax changes on jurisdictions where we do business, bio-pharmaceutical industry consolidations and relocations, and the trends on managing contract resources, all pose current and future challenges which may adversely affect our future performance. We believe that our future profitability and liquidity will be dependent on the effect the local and global economy, including any impacts of regional or global conflicts, price inflation, pandemics, changes in tax laws, worldwide life science manufacturing industry consolidations and restructurings, operational constraints imposed by our customers due to pandemics and resources management trends, will have on our operations, and our ability to seek service opportunities and adapt to industry trends.

14

Table of Contents

The following table sets forth information as to our revenue for the three-month periods ended January 31, 2026 and 2025, by geographic regions (dollars in thousands).

		Three months ended January 31,
Revenues by Region:		2026								2025
Puerto Rico		$	1,164				50.7	%		$	1,103				44.6	%
United States			547				23.8	%			646				26.2	%
Europe			584				25.5	%			721				29.2	%
Other			-				0.0	%			1				0.0	%
		$	2,295				100.0	%		$	2,471				100.0	%

For the three-month period ended January 31, 2026, the Company’s total revenues were approximately $2.3 million, a net decrease of approximately $0.2 million when compared to the same period last year.The European and US consulting markets had a decline in projects revenue of approximately $0.1 million each, while the Puerto Rico market had a negligible increase. As depicted below, when compared to the same period last year, overall gross profit had a 0.4 percentage point increase.

Results of Operations

The following table sets forth our statements of operations for the three-month periods ended January 31, 2026 and 2025 (dollars in thousands, and as a percentage of revenues):

		Three months ended January 31,
		2026								2025
Revenues		$	2,295				100.0	%		$	2,471				100.0	%
Cost of services			1,573				68.5	%			1,703				68.9	%
Gross profit			722				31.5	%			768				31.1	%
Selling, general and administrative expenses			816				35.6	%			860				34.8	%
Other income, net			131				5.7	%			102				4.1	%
Income before income taxes			37				1.6	%			10				0.4	%
Income tax expense			4				0.2	%			1				0.0	%
Net income			33				1.4	%			9				0.4	%

Revenues. For the three-month period ended January 31, 2026, the Company’s total revenues were approximately $2.3 million, a net decrease of approximately $0.2 million when compared to the same period last year. The European and US consulting markets had a decline in projects revenue of approximately $0.1 million each, while the Puerto Rico market had a negligible increase.

Cost of Services; Gross Profit. For the three-month period ended January 31, 2026, cost of services was approximately $1.6 million, a decrease of approximately $0.1 million, when compared to the same period last year. Overall gross profit had a 0.4 percentage points increase.

Selling, General and Administrative Expenses. For the three-month period ending January 31, 2026, selling, general and administrative expenses were approximately $0.8 million, sustaining a minor decrease when compared to the same period last year.

Other Income, Net. Other income, net for the three months ended January 31, 2026 was approximately $0.1 million. Other income, net, mainly represents (i) interest income, (ii) gain on the settlement of foreign exchange rates on intercompany balances, and (iii) gain on the disposition of a vehicle, in the amounts of $90,000, $34,000 and $7,000, respectively.

Net Income. For the three months ended January 31, 2026 and 2025, net income and net earnings per common share (both basic and diluted) were approximately breakeven.

15

Table of Contents

Liquidity and Capital Resources

Liquidity is a measure of our ability to meet potential cash requirements, including planned capital expenditures. As of January 31, 2026, the Company had approximately $10 million in working capital.

On June 13, 2014, the Board of Directors of the Company authorized the Repurchase Program. The Repurchase Program does not have an expiration date. During the three-month period ended January 31, 2026, the Company repurchased 3,100 of its shares of common stock. As of January 31, 2026, the Company has 1,446,192 shares of common stock available for future repurchases under the Repurchase Program.

Our primary cash needs consist of the payment of compensation to our consulting team, overhead expenses, and statutory taxes. Additionally, we may use cash for the repurchase of our common stock under the Repurchase Program, capital expenditures and business development expenses. Management believes that based on the current level of working capital, operations and cash flows from operations, and the collectability of high-quality customer receivables are sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments for and beyond the next twelve months.

While uncertainties relating to the current local and global economic conditions, competition, the industries and geographical regions served by us and other regulatory matters exist within the consulting services industry, as described in this Quarterly Report on Form 10-Q, management is not aware of any other trends or events likely to have a material adverse effect on liquidity or its financial statements.

Off-Balance Sheet Arrangements

We were not involved in any significant off-balance sheet arrangement during the three months ended January 31, 2026.

Critical Accounting Policies and Estimates

There were no material changes during the three months ended January 31, 2026 to the critical accounting policies reported in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025.

New Accounting Pronouncements

There were no new accounting standards issued since our filing of the Annual Report on Form 10-K for the fiscal year ended October 31, 2025, which could have a significant effect on our condensed consolidated financial statements.

Forward-Looking Statements

Our business, financial condition, results of operations, cash flows and prospects, and the prevailing market price and performance of our common stock, may be adversely affected by a number of factors, including the factors set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended October 31, 2025 and this Quarterly Report on Form 10-Q. Certain statements and information set forth in this Quarterly Report on Form 10-Q, as well as other written or oral statements made from time to time by us or by our authorized executive officers on our behalf, constitute “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These statements include all statements other than those made solely with respect to historical fact and identified by words such as “believes,” “anticipates,” “expects,” “intends” and similar expressions, but such words are not the exclusive means of identifying such statements. We intend for our forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we set forth this statement and these risk factors in order to comply with such safe harbor provisions. You should note that our forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q or when made and we undertake no duty or obligation to update or revise our forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Although we believe that the expectations, plans, intentions and projections reflected in our forward-looking statements are reasonable, such statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks, uncertainties and other factors that our stockholders and prospective investors should consider include, but are not limited to, those set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended October 31, 2025 and this Quarterly Report on Form 10-Q.

16

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

Changes in Internal Control Over Financial Reporting

Based on an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, there has been no change in our internal control over financial reporting during our last fiscal quarter identified in connection with that evaluation that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

17

Table of Contents

PART II– OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

From time to time, we may be a party to legal proceedings incidental to our business. Currently, there are no proceedings threatened or pending against us, which, if determined adversely to us, would have a material effect on our financial position or results of operations and cash flows. However, the Company is a complainant in one legal proceeding as described below.

On March 15, 2023, the Company’s subsidiaries Pharma-Bio Serv PR, Inc., Pharma Serv, Inc. and Scienza Labs, Inc., filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC and Romark Holdings, LLC (collectively, “Romark”), before the Commonwealth of Puerto Rico Court of First Instance, San Juan Superior Section. On November 13, 2023, a judgment was entered by the Court ordering Romark to pay jointly to the Company’s subsidiaries $6,717,431.69, which includes the principal amount of $5,246,782, plus interest up to the date of the judgment. The Company’s subsidiaries are pursuing assets and monies from Romark to collect the judgment. To this date, however, we have been unable to identify assets of Romark against which to collect. Also, multiple other creditors of Romark have filed claims against it. Aside from legal fees and the costs of identifying assets, and costs of collection efforts, no further losses are expected. The Company’s subsidiaries will continue the collection efforts with Romark. However, we cannot guarantee a successful outcome in collecting the funds owed to the Company’s subsidiaries.

ITEM 1A.  RISK FACTORS.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the year ended October 31, 2025.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

(c) The following table provides information about purchases by the Company of its shares of common stock during the three-month period ended January 31, 2026:

Period		Total Number of Shares Purchased				Average Price Paid per Share				Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1)				Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (1)
November 1, 2025 through November 30, 2025			-			$	-				-				1,449,292
December 1, 2025 through December 31, 2025			-			$	-				-				1,449,292
January 1, 2026 through January 31, 2026			3,100			$	0.54				3,100				1,446,192
Total			3,100			$	0.54				3,100

(1) On June 16, 2014, the Company announced that the Board of Directors of the Company approved the Repurchase Program authorizing the Company to repurchase up to two million shares of its outstanding common stock. The timing, manner, price and amount of any repurchases under the Repurchase Program will be at the discretion of the Company, subject to the requirements of the Exchange Act Rules. The Repurchase Program does not oblige the Company to repurchase any shares and it may be modified, suspended or terminated at any time and for any reason. The Repurchase Program has no expiration date. No shares will be repurchased under the Repurchase Program directly from directors or officers of the Company.

18

Table of Contents

ITEM 6. EXHIBITS

(a) Exhibits:

31.1		Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of the chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase
104		Cover page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

____________

* Furnished herewith.

19

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHARMA-BIO SERV, INC.

/s/ Victor Sanchez

Victor Sanchez

Chief Executive Officer and

President Europe Operations

(Principal Executive Officer)

/s/ Pedro J. Lasanta

Pedro J. Lasanta

Chief Financial Officer, Vice President Finance and

Administration, and Secretary

(Principal Financial Officer and

Principal Accounting Officer)

Dated: March 17, 2026

20

FAQ

How did Pharma-Bio Serv (PBSV) perform financially in the quarter ended January 31, 2026?

Pharma-Bio Serv generated modest profit with lower revenue. Revenue was about $2.3 million versus $2.5 million a year earlier, but net income improved to $32,860 as gross margin stayed near 31.5% and other income of $131,025 offset a small operating loss.

What were Pharma-Bio Serv (PBSV) earnings per share for the January 31, 2026 quarter?

Earnings per share were essentially breakeven. The company reported basic and diluted earnings per common share of $0.001 for the three months ended January 31, 2026, reflecting net income of $32,860 spread over roughly 22.9 million weighted average shares outstanding.

What is Pharma-Bio Serv’s liquidity position as of January 31, 2026?

Pharma-Bio Serv reported a strong cash and working capital position. The company held $5.8 million in cash and cash equivalents plus $4.8 million in marketable U.S. Treasury securities, with total working capital of about $10 million, which management believes is sufficient to cover anticipated needs beyond the next twelve months.

Did Pharma-Bio Serv (PBSV) pay or declare a dividend for this quarter?

The board declared a cash dividend during the quarter. On January 28, 2026, it approved a $0.075 per common share dividend for shareholders of record on February 27, 2026, for an aggregate expected payment of approximately $1,717,627 around March 20, 2026.

How are Pharma-Bio Serv’s revenues distributed across regions in Q1 2026?

Revenue was diversified across Puerto Rico, U.S., and Europe. For the three months ended January 31, 2026, Puerto Rico generated $1,164 thousand (50.7%), the United States $547 thousand (23.8%), Europe $584 thousand (25.5%), and other regions were negligible, for total revenue of $2,295 thousand.

What is the status of Pharma-Bio Serv’s legal judgment against Romark?

The company holds a judgment but collection remains uncertain. In November 2023, subsidiaries obtained a $6,717,431.69 judgment against Romark entities, including $5,246,782 principal plus interest. Management continues collection efforts but has not yet identified Romark assets to satisfy the judgment amid multiple other creditor claims.

Did Pharma-Bio Serv (PBSV) repurchase any shares in the January 31, 2026 quarter?

The company made a small share repurchase under its program. During January 2026, it bought back 3,100 common shares at an average price of $0.54. As of January 31, 2026, 1,446,192 shares remained authorized for repurchase under the ongoing stock repurchase program.